# GLP-1 Digestive Risks in 55 Placebo Trials: Extra Cases per 1,000 | Buy This GLP

A meta-analysis of 55 placebo-controlled trials | GLP-1 drugs added about 2 gallstone and 4 reflux cases per 1,000, with uncertainty around rarer outcomes.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/glp1-gallstones-and-reflux-pooled
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Digestive Risks in 55 Placebo Trials: Extra Cases per 1,000

Pooling 106,395 participants, gallstones rose by about 2 cases per 1,000 and the review estimated about 4 additional reflux cases per 1,000.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20265 min readUpdated November 2026

Extra cases per 1,000 people treated · gallstones · 2 more in 1,000 · reflux · 4 more in 1,000 · 55 trials, 106,395 participants

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A meta-analysis pooled 55 placebo-controlled randomized trials covering 106,395 participants.
-   Gallstones went up: RR 1.46, 95% CI 1.09 to 1.97. That is about 2 extra cases per 1,000 people.
-   Reflux probably increased: RR 2.19, 95% CI 1.48 to 3.25. About 4 extra cases per 1,000.
-   The review judged that treatment probably had little or no effect on the other gastrointestinal and biliary outcomes it examined.
-   Rare outcomes can remain uncertain even when trials are pooled.

The review estimated about four additional diagnoses of gastroesophageal reflux disease per 1,000 people treated, compared with placebo [\[1\]](https://buythisglp.com/research/glp1-gallstones-and-reflux-pooled#ref-1). That figure describes the difference in risk, rather than the total number of people who developed reflux.

## What was pooled

Our [GLP-1 side-effect guide](https://buythisglp.com/research/what-are-the-side-effects-of-a-glp1) covers common symptoms such as nausea. This review searched five databases for placebo-controlled randomized trials that reported specific gastrointestinal and biliary events in type 2 diabetes, overweight or obesity, and fatty liver disease. It included 55 trials and 106,395 participants [\[1\]](https://buythisglp.com/research/glp1-gallstones-and-reflux-pooled#ref-1).

## Two things went up

Gallstones. The risk ratio was 1.46, 95% CI 1.09 to 1.97, which the authors translate as about 2 extra cases per 1,000 people treated. Reflux. The risk ratio was 2.19, 95% CI 1.48 to 3.25, or about 4 extra cases per 1,000.

The 46% relative increase in gallstone risk corresponded to about two extra cases per 1,000 people at the baseline risk used in this review. Our [gallbladder risk guide](https://buythisglp.com/research/do-glp1-drugs-cause-gallbladder-problems) explains why estimates differ across outcomes and studies. A person's baseline risk affects the absolute difference.

## What the review found for other outcomes

The authors judged that treatment probably had little or no effect on the other outcomes they studied, including pancreatitis, bowel obstruction, gastrointestinal bleeding and gastroparesis.

Rare events can be hard to measure even across many trials. The pooled results leave uncertainty about how much risk changes for some outcomes.

The subgroups did not reach significance

The review reports that the gallstone and reflux risks looked larger in trials of people with overweight or obesity, in the agents that produce more weight loss, and at higher doses. It also reports that those subgroup effects were not statistically significant. Both sentences belong together. Taken alone, the first reads as a dosing warning it has not earned.

## What to check about follow-up care

Our [guide to advertised and billed prices](https://buythisglp.com/research/glp1-headline-vs-billed-price) explains why a medication quote and the cost of clinical care can differ. Ask who handles new symptoms during treatment and whether follow-up visits carry a separate charge.

## Frequently asked

How much does gallstone risk actually rise?

The pooled risk ratio was 1.46, 95% CI 1.09 to 1.97, which the review states as roughly 2 extra cases per 1,000 people treated. Both framings describe the same result.

Does it cause pancreatitis?

The review judged that GLP-1 treatment probably had little or no effect on pancreatitis risk in the trials it examined. Rare events can still be difficult to estimate.

Is the risk higher at higher doses?

It looked that way and the difference did not reach statistical significance. The same applies to trials in obesity and to the agents producing the most weight loss, so treat it as a hypothesis rather than a dosing rule.

What should I budget for?

Ask what the quoted price covers and what you would pay separately for follow-up visits or testing.

## Sources

1.  \[1\] Chiang CH, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis Gastroenterology. [PMID 40499738](https://pubmed.ncbi.nlm.nih.gov/40499738/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
